Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection
New Microbiologica
; 44(3):135-144, 2021.
Article
in English
| GIM | ID: covidwho-1716857
ABSTRACT
Neutralizing monoclonal antibody therapies against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) play a significant role both in the prevention and treatment of the coronavirus disease 2019 (COVID-19). In this review we discuss the monoclonal antibody therapies that have received preliminary authorization for use in COVID-19 patients by the U.S. Food and Drug Administration or the European Medicines Agency. We review here their mechanisms of action, their efficacy in prophylaxis and treatment, their indications for use, and the impact of SARS-CoV-2 variants of concern on their activity.
monoclonal antibodies; prophylaxis; coronavirus disease 2019; disease prevention; drugs; neutralization; human diseases; viral diseases; Severe acute respiratory syndrome coronavirus 2; man; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; SARS-CoV-2; medicines; pharmaceuticals; viral infections
Search on Google
Collection:
Databases of international organizations
Database:
GIM
Language:
English
Journal:
New Microbiologica
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS